Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade | Zendy

Feng Wang | Zendy; Qian Yin | Zendy; Liang Chen | Zendy; Mark M. Davis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade

Author(s) -

Feng Wang,

Qian Yin,

Liang Chen,

Mark M. Davis

Publication year - 2017

Publication title -

proceedings of the national academy of sciences

Language(s) - English

Resource type - Journals

eISSN - 1091-6490

pISSN - 0027-8424

DOI - 10.1073/pnas.1712901115

Subject(s) - blockade , autoimmunity , ctla 4 , context (archaeology) , medicine , immunology , bifidobacterium , antibody , biology , t cell , lactobacillus , immune system , bacteria , receptor , paleontology , genetics

Significance The major stumbling block in the use of checkpoint inhibitors for cancer treatment is the severe autoimmunity that often results. In this study, we found the toxicity of a checkpoint blockade antibody can be ameliorated via administration ofBifidobacterium , a widely available probiotic. These results suggest that it may be possible to mitigate the autoimmunity caused by anti–CTLA-4 and perhaps other checkpoint inhibitors by manipulating gut microbiota.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research